---
document_datetime: 2024-11-27 14:48:47
document_pages: 54
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dafiro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: dafiro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 121.7917355
conversion_datetime: 2025-12-19 21:40:43.368162
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dafiro

Proceduralstepstakenandscientificinformationaftertheauthorisation

| Application number   | Scope                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued2 / amended on   | Product Information affected3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IG/1804              | B.II.b.2.c.1-Change to importer,batch release arrangements andquality controltestingof theFP- Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Not includingbatch control/testing | 21/11/2024                          |                                            | Annex II and PL                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex I, Labelling, PL (Package Leaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annexII, labelling,package leaflet).The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a)of Regulation(Eu)No.712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | B.Ill.1.a.2-Submissionofanew/updatedor deletion of Ph. Eur. Certificate of Suitability to the relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                        | 28/08/2024   | n/a   |             | IG/1784   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|-----------|
| IG/1763 | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                  | 04/07/2024   | n/a   |             |           |
| IG/1708 | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                         | 08/04/2024   | n/a   |             |           |
|         | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                          | 25/01/2024   |       | SmPC and PL | WS/2610   |
|         | This was an applicationfor a group of variations. A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranASMFholder or supplier of the AS, starting material, reagent or intermediateused in themanufactureof theASor manufacturerofanovelexcipient A.4-Administrative change-Changein thename and/or address of a manufacturer or an ASMF holder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient | 14/09/2023   | n/a   |             | IG/1666/G |

<div style=\"page-break-after: always\"></div>

| IG/1644/G   | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                          | 08/08/2023   | n/a   |                                                                                                                                                                                                                                                                                                     |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1637     | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                            | 19/07/2023   | n/a   |                                                                                                                                                                                                                                                                                                     |
|             | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess | 02/03/2023   | n/a   | WS/2363/G B.II.b.3.a-Change in the manufacturing process of the finished or intermediate product - Minor change inthemanufacturingprocess B.II.b.4.a -Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | in the manufacturing process B.II.b.4.a -Change in the batch size (including batch sizeranges)of the finishedproduct-Up to10-fold comparedtotheoriginallyapprovedbatchsize B.II.b.4.a-Change in the batch size(includingbatch size ranges) of the finished product -Up to 10-fold comparedtotheoriginallyapprovedbatchsize                                                                                                    |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1598/G | Thiswas an applicationfor a group of variations. A.7-Administrative change-Deletion of manufacturingsites A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                           | 28/02/2023 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| WS/2337/G | This was an application for a group of variations following a worksharing procedure according to Article 20of CommissionRegulation(EC)No 1234/2008. C.I.z-Changes(Safety/Efficacy)ofHumanand VeterinaryMedicinalProducts-Othervariation C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of wording agreed by the competent authority | 10/11/2022 | 06/11/2023 | SmPC and Annex II | C.I.z-To update section4.9of theSmPC,toimplement thewordingrelatedtotheriskofnon-cardiogenic pulmonary oedema in amlodipine overdose. C.I.11.a-To update Annex II to reflect the fulfilment of ConditionB,assetoutbytheCommissionDecisionasan outcomeoftheassessmentfortheimpactoftheArticle 5(3)scientificopinion onnitrosaminesinhumanmedicinal products on the opinion adopted pursuant to Article 31 of Directive2001/83/ECforangiotensin-II-receptor antagonists (sartans) containing a tetrazole group. |

<div style=\"page-break-after: always\"></div>

| WS/2278/G   | Thiswas an applicationfor agroupofvariations following aworksharingprocedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.III.1.a.3-Submission of a new/updated or deletion ofPh.Eur.Certificate ofSuitability to the relevantPh.Eur.Monograph-New certificate from a new manufacturer (replacement or addition) B.I.a.1.f -Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place                                                                                                                      | 27/10/2022   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| WS/2256/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation(EC) No 1234/2008. B.II1.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificate of Suitability tothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits corresponding test method B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure | 02/06/2022   | n/a   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.a -Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate- Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f-Changein themanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacement or additionofasitewhere batchcontrol/testingtakesplace   |            |     |                                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| PSUSA/10344 /202106 | PeriodicSafetyUpdateEUSingleassessment- amlodipine / valsartan, amlodipine / hydrochlorothiazide/valsartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/02/2022 | n/a | PRACRecommendation-maintenance |
| IG/1439/G           | Thiswasanapplicationforagroupofvariations. B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor                                                                                                                                                                                                                                                                                                                                                                                                           | 15/10/2021 | n/a |                                |

<div style=\"page-break-after: always\"></div>

|           | intermediateusedin themanufactureof theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                 |                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------|
| IG/1438/G | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturing sites A.5.b-Administrative change-Change in the name and/oraddressof amanufacturer/importerof the finishedproduct,including quality control sites (excluding manufacturer for batch release) B.11.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsible for importation and/or batch release - | 05/10/2021 | 21/09/2022 | Annex II and PL | Not includingbatch control/testing |
|           | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.1.11.z -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation，includingtheRMP-Othervariation                                                                                                                                                                                                                   | 02/09/2021 | 11/10/2021 | Annex II        | WS/2109                            |
|           | This was an application for a group of variations. C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreedbythecompetentauthority C.1.11.a -Introduction of, or change(s) to, the                                                                                                                                                                                                     | 26/04/2021 | 11/10/2021 | Annex II        | IG/1383/G                          |

<div style=\"page-break-after: always\"></div>

|           | obligations and conditions of a marketing authorisation,including the RMP-Implementation of wordingagreedbythecompetent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| WS/2041/G | Thiswasanapplicationforagroupofvariations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. B.II.d.2.d -Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a-Change in test procedure for the finished product-Minorchangestoanapproved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 22/04/2021 | n/a | procedure |
|           | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.I.b.1.h -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)of a specification parameter as a result of a safety or quality issue                                                                                                                                                                                                                | 15/04/2021 | n/a | WS/2019   |

<div style=\"page-break-after: always\"></div>

| WS/2022/G   | This was an applicationfor a group ofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.c-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specificationparametertothespecificationwith its corresponding test method B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitability tothe relevantPh.Eur.Monograph-Updatedcertificate from an already approved manufacturer   | 15/04/2021   | n/a        |                 |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|
| WS/2023/G   | This was an applicationfor a group ofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.c.2-Change to importer,batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s)takeplace,exceptbatch-                                                                                                                                                                                                                                                                                                                                   | 25/03/2021   | 11/10/2021 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          | release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.z-Change in the manufacturing process of thefinishedorintermediateproduct-Othervariation B.II.e.4.a - Change in shape or dimensions of the container or closure(immediate packaging)-Non- sterilemedicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |          |                                                                     |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|---------------------------------------------------------------------|
| A31/0101 | TheEuropeanCommissiontriggeredareferral under Article31ofDirective2001/83/EC andrequested the CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinalproducts and to issue arecommendation on whether therelevantmarketing authorisations should be maintained,varied, suspended or revoked. During theCHMPplenarymeetinginSeptember 2018,thescopeof thereferral hasbeenwidened to include all sartans with a tetrazole group in their molecularstructure(candesartan,irbesartan, losartan,olmesartan andvalsartan).The CHMP Opinionwasissuedon31January2019and the CommissionDecisionwas issued on2April 2019. In aletterdated29July2020,theEuropean CommissionrequestedtheEMAtoassesstheimpact of theoutcomeof theArticle5(3)assessmenton nitrosaminesadoptedon25June2020on the CHMP'sopinionof31January2019forthescientific assessment and review under Article 31 of Directive 2001/83/EC regarding angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471).The CHMP was requested to | 12/11/2020 | 12/02/2021 | Annex II | Pleaserefertotheassessmentreport: DafiroEMEA/H/A-31/1471/C/776/0101 |

<div style=\"page-break-after: always\"></div>

|         | the Marketing Authorisations shouldbevaried.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |          |           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------|
| WS/1946 | Thiswasanapplicationforavariationfollowinga worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.II.b.3.z-Change in the manufacturing process of thefinishedorintermediateproduct-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/01/2021 | n/a        |          |           |
| IG/1319 | B.II.e.6.b -Change in any part of the (primary) packaging material not in contact with the finished productformulation-Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 07/12/2020 | n/a        |          |           |
|         | Thiswas anapplicationfor agroupofvariations. A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufacture of theASor manufacturer of a novel excipient B.I.a.1.f-Changein themanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacement or additionofasitewhere batch control/testing takes place B.I.b.1.h-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)ofa | 21/10/2020 | 11/10/2021 | Annex II | IB/0116/G |

<div style=\"page-break-after: always\"></div>

| specification parameter as a result of a safety or quality issue B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate- Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.z-Change in test procedure forAS or starting material/reagent/intermediate - Other variation B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevantPh.Eur.Monograph-Updatedcertificate from an already approved manufacturer B.II1.1.a.2-Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer B.Ill.1.a.3-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-New certificatefrom a newmanufacturer(replacement or addition)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | Minor changeinlabellingorpackageleafletnot connected with the SPC(Art.61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                       | 03/07/2020   | 11/10/2021   | PL       | N/0115                            |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------|-----------------------------------|
| IG/1254/G | This was an application for a group of variations. A.4-Administrativechange-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerofanovelexcipient B.I.a.1.f-Change in themanufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere            | 15/05/2020   | n/a          |          | batch control/testing takes place |
| IG/1174/G | Thiswas anapplicationfor agroupofvariations. A.5.b-Administrative change-Change in the name and/oraddressof amanufacturer/importerofthe finished product, including quality control sites (excluding manufacturer for batch release) A.7-Administrativechange-Deletionof manufacturingsites B.II.b.2.a-Change to importer,batch release arrangements and quality control testing of the FP - Replacement/additionofasitewherebatch control/testing takes place | 11/12/2019   | n/a          |          |                                   |
| WS/1656/G | Thiswas an applicationfor agroupofvariations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No                                                                                                                                                                                                                                                                                                                              | 31/10/2019   | 26/06/2020   | Annex II |                                   |

<div style=\"page-break-after: always\"></div>

| 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.I.a.1.f-Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in themanufacturer ofASor of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takesplace B.I.b.1.h-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent -Addition or replacement (excl. Biol. or immunol. substance) of a specificationparameterasaresultofasafetyor quality issue B.I.b.1.h-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.2.a-Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.I.b.2.z-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other variation |

<div style=\"page-break-after: always\"></div>

| IG/1111/G   | Thiswas an applicationfor a groupofvariations. B.I.a.1.f-Change in themanufacturer of ASor of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS-replacement or addition of a site where batch control/testing takes place B.II1.1.a.3-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph.Eur.Monograph-New certificate from a           | 08/08/2019   | n/a        |                 | new manufacturer(replacement or addition)   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|---------------------------------------------|
|             | This was an application for a group of variations. A.7-Administrative change-Deletion of manufacturing sites B.II.b.1.a-Replacement or addition of a manufacturing site for the Fp - Secondary packaging site B.11.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsible for importation and/or batch release - Notincludingbatchcontrol/testing | 16/07/2019   | 26/06/2020 | Annex II and PL | IG/1116/G                                   |
| IG/1112     | C.1.11.a-Introduction of,or change(s) to,the obligations and conditions of a marketing authorisation,including theRMP-Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                         | 05/07/2019   | n/a        |                 |                                             |
| IG/1100     | A.7-Administrativechange-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                  | 24/05/2019   | n/a        |                 |                                             |

<div style=\"page-break-after: always\"></div>

| IG/1099   | A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                      | 24/05/2019   | n/a        |                            | manufacturing sites   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------|-----------------------|
| IG/1098   | B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.Certificateof Suitability tothe relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                    | 29/04/2019   | n/a        |                            |                       |
|           | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                                                                            | 05/02/2019   | 26/06/2020 | PL                         | N/0105                |
| IG/0986   | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                      | 17/10/2018   | 02/04/2019 | Annex II, Labelling and PL |                       |
| IG/0975/G | This was an application for a group of variations. B.I.a.1.f-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changes toquality controltesting arrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.III.1.a.1 -Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph. Eur. Monograph - New certificate from an alreadyapprovedmanufacturer | 10/09/2018   | n/a        |                            |                       |
| IG/0958/G | This was an application for a group of variations. B.II.c.1.a-Change in the specificationparameters and/or limits of an excipient -Tightening of                                                                                                                                                                                                                                                                                               | 21/08/2018   | n/a        |                            |                       |

<div style=\"page-break-after: always\"></div>

| B.II.d.1.a - Change in the specification parameters and/or limits of thefinishedproduct-Tightening of specification limits B.II.d.1.a-Change in the specificationparameters and/orlimits of thefinishedproduct-Tightening of specification limits B.II.d.1.c-Change in the specification parameters and/orlimits of thefinishedproduct-Addition of a newspecificationparameter to the specification with its corresponding test method   |            |            |                        | specification limits   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------|
| A.5.b - Administrative change - Change in the name and/oraddressofamanufacturer/importerofthe finished product, including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                                   | 21/06/2018 | n/a        |                        | IG/0947                |
| TransferofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                                                         | 16/05/2018 | 07/06/2018 | SmPC, Labelling and PL | T/0099                 |
| C.I.3.a - Change(s) in the SPC, Labelling or PL intended toimplementtheoutcomeofaprocedure concermingPSURorPASSortheoutcomeofthe assessmentdoneunderA45/46-Implementationof wording agreed by the competent authority                                                                                                                                                                                                                    | 17/04/2018 | 07/06/2018 | SmPC and PL            | IG/0910                |
| This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No                                                                                                                                                                                                                                                                                             | 15/03/2018 | n/a        |                        | WS/1291/G 1234/2008.   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.b-Change in test procedure for AS or starting material/reagent/intermediate -Deletion of a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b -Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a testprocedurefortheASorastarting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Deletionof a testprocedurefortheASorastarting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b -Change in test procedure forAS or   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | a testprocedurefortheASorastarting material/reagent/intermediate,if an alternativetest procedure is already authorised B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate -Deletion of a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate   |            |     |                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| IG/0863             | A.4-Administrative change-Changein thename and/oraddressof amanufactureror anASMFholder orsupplieroftheAS,startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                                                                                                              | 01/12/2017 | n/a |                                |
| IG/0805             | A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/05/2017 | n/a |                                |
| PSUSA/10344 /201606 | PeriodicSafetyUpdateEUSingleassessment- amlodipine/valsartan,amlodipine/ hydrochlorothiazide/valsartan                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/03/2017 | n/a | PRACRecommendation-maintenance |
| IG/0776             | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                | 23/02/2017 | n/a |                                |

<div style=\"page-break-after: always\"></div>

| WS/1080   | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/02/2017   | 30/01/2018   | SmPC and PL   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|
| IG/0751/G | Thiswas an applicationfor a group of variations. A.7-Administrativechange-Deletion of manufacturingsites A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/12/2016   | n/a          |               |
| IG/0727/G | This was an application for a group of variations. B.I.a.1.f -Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.1.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.1.b.2.a-Change in testprocedure forAS or | 14/09/2016   | n/a          |               |

<div style=\"page-break-after: always\"></div>

|         | startingmaterial/reagent/intermediate-Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0707 | B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace                                                                                                                                                                                                                                                               | 21/07/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IG/0706 | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                            | 21/07/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| N/0086  | Updateofthepackageleafletwithrevisedcontact details of the local representative for Germany. Minor change in labelling or package leaflet not connected with theSPC(Art.61.3 Notification)                                                                                                                                                                                                                                                                                              | 20/04/2016 | 30/01/2018 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| WS/0709 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Changesrelated tothe amlodipine component Updateofsection4.2oftheSmPCtoincluderevised dosingrecommendations inpatientswithhepatic impairment and in elderly patients. Changesrelatedtothevalsartancomponent Updateofsections4.2and4.3of theSmPCto removethecontraindicationrelated topatientswith severerenalimpairment andpatientsundergoing | 26/03/2015 | 05/05/2015 | SmPC and PL | Theremoval of thecontraindicationrelated topatientswith severe renal impairment and patients undergoing dialysis, is editorial innature and is implemented toalign the product information with the decision from Article 30 Referralprocedure(EMEAprocedurenumber:EMEA/H/A- 30/998) concluded for Diovan in Nov 2008.As an oversight, this wasnot applied to theExforgeproduct information at the time. The posology section is updated to highlight that when switchingeligiblehypertensivepatientswithhepatic impairmentorelderlyhypertensivepatientstoamlodipine orExforge,thelowestavailabledoseof amlodipine |

<div style=\"page-break-after: always\"></div>

|           | dialysis and section 4.8 of the SmPC to update the Preferred Term asper MedDRAversion17. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and the Package Leaflet C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                             |            |     |             | monotherapy or of the amlodipine component, respectively, should be used.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-----------------------------------------------------------------------------|
| IG/0539   | C.I.1.a - Change(s) in the SPC, Labelling or PL intended to implement the outcomeof a Union referral procedure-The product isnot coveredby thedefinedscopeoftheprocedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/03/2015 |     | SmPC and PL |                                                                             |
| IG/0536/G | This was an application for a group of variations. B.I.b.1.c-Change in thespecificationparameters and/or limits of an AS, starting material/intermediate/reagent -Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.1.b.2.a-Change in test procedure forAS or | 11/03/2015 | n/a |             |                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.IIl.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                 |            |     |           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IG/0528/G | Thiswas anapplicationfor a group of variations. A.4-Administrative change-Change in thename and/oraddressof amanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturer of a novel excipient B.1.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c-Change in the specification parameters and/or limits of anAS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod | 17/02/2015 | n/a |           |
|           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/oraddressofamanufacturer/importerofthe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/01/2015 | n/a | IG/0523/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | finished product, including quality control sites (excludingmanufacturerforbatchrelease) A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                        |                                                                    |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------|
| IG/0514   | A.1-Administrative change-Change in the name and/oraddressoftheMAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/12/2014 | 05/05/2015 | SmPC, Labelling and PL |                                                                    |
| WS/0632/G | Thiswasanapplicationfor agroupofvariations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. Toimplementchangesinthemanufacturingprocess of the active substance. B.I.a.2.z-Changes in the manufacturing process of the AS-Other variation B.I.a.2.z-Changes in the manufacturing process of the AS-Other variation B.I.a.2.z - Changes in the manufacturing process of theAS-Othervariation B.I.a.2.z-Changes in the manufacturing process of the AS-Other variation B.I.a.2.a-Changes in the manufacturing process of theAS-Minor change in the manufacturingprocess of theAS B.I.a.2.a-Changes in the manufacturingprocess of theAS-Minorchangein themanufacturingprocess of the AS | 23/10/2014 | n/a        |                        | Toimplementchangesin themanufacturingprocessof the activesubstance |

<div style=\"page-break-after: always\"></div>

|           | the AS - Minor change in the manufacturing process of the AS B.I.a.2.a-Changes in the manufacturing process of the AS - Minor change in the manufacturing process of theAS B.I.a.4.z-Change to in-process tests orlimits applied during the manufacture of the AS - Other variation B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent -Addition of a new specification parameter to the specification with its corresponding test method                                                                                                        |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/0630/G | This was an application for a group of variations followingaworksharingprocedure accordingto Article20ofCommissionRegulation(EC)No 1234/2008. Replacement of 2 test methods for an active substance intermediate. Toincude a minor change in a test methodfor an activesubstanceintermediate. Toadd3testmethodsforan activesubstance intermediate. To change the specification parameter for an active substance intermediate. B.I.b.2.e -Change in test procedure forAS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting | 23/10/2014 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | material/intermediate B.I.b.2.a -Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.b-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.2.e-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its   |            |     |                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------|
| WS/0629/G | This was an application for a group of variations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 23/10/2014 | n/a | Toreplace3testmethodsforanactivesubstance intermediate. To include a minor change to an approved test procedure |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 1234/2008.                                                                                                                                                                 | foran activesusbatcneintermediate. Toadd a testmethod or an activesubstanceintermediate.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Toreplace3testmethodsfor anactivesubstance intermediate.                                                                                                                   | Toadd 2 alternativetestmethodsfor anactivesubstance                                        |
| To include a minor change to an approved test procedure for an active susbtance intermediate.                                                                              | intermediate.                                                                              |
| To add a testmethodor an activesubstance intermediate.                                                                                                                     |                                                                                            |
| Toadd2alternativetestmethodsfor anactive substance intermediate.                                                                                                           |                                                                                            |
| B.I.b.2.e -Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting |                                                                                            |
| material/intermediate B.I.b.2.e -Change in test procedure forAS or                                                                                                         |                                                                                            |
| starting material/reagent/intermediate - Other                                                                                                                             |                                                                                            |
| changestoa testprocedure(includingreplacement or addition) for the AS or a starting                                                                                        |                                                                                            |
| material/intermediate B.I.b.2.e-Change in test procedure forAS or                                                                                                          |                                                                                            |
| starting material/reagent/intermediate - Other                                                                                                                             |                                                                                            |
| changes to a test procedure (including replacement                                                                                                                         |                                                                                            |
| or addition) for the AS or a starting                                                                                                                                      |                                                                                            |
| material/intermediate                                                                                                                                                      |                                                                                            |
| B.I.b.2.a-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Minor                                                                                     |                                                                                            |
| changes to an approved test procedure                                                                                                                                      |                                                                                            |
| B.I.b.1.c -Change in the specification parameters                                                                                                                          |                                                                                            |
| and/or limits of an AS, starting                                                                                                                                           |                                                                                            |
| material/intermediate/reagent-Additionofanew                                                                                                                               |                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | specification parameter to the specification with its corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c-Change in thespecificationparameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                   |            |     |      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| WS/0631/G | Thiswas an applicationfor agroupofvariations following aworksharingprocedure accordingto Article20of CommissionRegulation(EC)No 1234/2008. Toadd an alternativemanufacturerofAS intermediates. ToincreasethebatchsizesforASintermediatesfor thenewmanufacturingsite Todeletea manufacturingsiteforASintermediates. B.I.a.1.z-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS-Other variation B.I.a.3.a-Change inbatch size(including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch | 23/10/2014 | n/a | size |

<div style=\"page-break-after: always\"></div>

|          | manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             |                             |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------|
| A31/0069 | On17April2013,furthertotheemergence ofnew evidencefrom thescientificliteratureondualRAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of CouncilDirective2001/83/EC,requestingthe PharmacovigilanceRiskAssessmentCommittee (PRAC) toissue a recommendation on thebenefit- risk of dual RAS blockade therapy through the combineduseofangiotensin-convertingenzyme inhibitors(ACE-inhibitors), angiotensin II receptor blockers(ARBs)oraliskirenand todetermine whether any regulatory measures should be taken on themarketing authorisations of theproducts | 22/05/2014 | 04/09/2014 | SmPC and PL | involved in this procedure. |
|          | Thiswas an applicationfor a group of variations. A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturing sites B.I.a.1.f-Change in the manufacturer ofASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltesting arrangementsfor the AS-replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                        | 26/03/2014 | n/a        |             | IG/0424/G                   |

<div style=\"page-break-after: always\"></div>

| WS/0516   | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.8oftheSmPCtoincludethe ADR'bullous dermatitis'. C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                   | 20/03/2014   | 04/09/2014   | SmPC   | The MAH has submitted a comprehensive report with the purposeofreviewingthepotentialassociationofskin events with valsartan containingmedications,including ExforgeandExforgeHCTandrespectiveclones.Itis consideredjustified toupdatethelistofADRsinsection4.8 'undesirable effects'of the Exforge SmPC and Exforge HCT SmPCandtheirrespectiveclonesbasedonadditional informationfromasmallnumberofpost-marketingcases reportingbullous rash occurring withvalsartan.This amendmentdoesnotchange thebenefitriskbalancefor these products which remains positive.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0495/G | Thiswas an applicationfor a groupofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. -changeinthespecificationlimitsofsome intermediatesusedinthemanufactureoftheactive substance, - addition of a new specification parameters with theircorrespondingtestmethodsto thespecification ofsome intermediatesused in themanufacture of theactivesubstance and -changeintestproceduresforsomeintermediates used in themanufacture of the activesubstance. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.b-Change in the specificationparameters | 20/02/2014   | n/a          |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of an AS, starting material/intermediate/reagent-Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.e -Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in testprocedure forAS or starting material/reagent/intermediate- Other changes to a testprocedure(includingreplacement   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | material/intermediate B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.1.c-Change in thespecificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0377/G | Thiswas anapplicationfor a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod                     | 22/11/2013 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                      |
| WS/0461   | Thiswas anapplicationfor avariationfollowing a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.5of theSmPCtoincludefurther informationregardinganinteractionbetween valsartan and lithium.                                                                                                                                                                                            | 21/11/2013 | 04/09/2014 | SmPC | The MAH has reviewed the clinical databases of four large outcomesstudies(Val-HeFT,Value,Valiant,and Navigator) foradverseeventreports of lithiumtoxicity.Further,the NovartisSafetyDatabase(ARGUS)wassearchedfor all caseswherebothvalsartanandlithiumwerereportedas co-administered,and aliterature searchwasperformedfor published studies. Theavailabledatasuggestapossiblereversibleinteraction |

<div style=\"page-break-after: always\"></div>

|         | C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                       | between valsartan and lithium, although the exact mechanismhasnotbeenestablished.The dataidentified arelimited andnoconfirmatoryevidencewasavailable from the clinical trials performed. TheSmPChasbeenupdated toinformprescribersof the fact that reversible increases in serum lithium concentrations and toxicity have been reported during concomitantadministration of lithium with angiotensinII receptor antagonistsincludingvalsartan.Therefore,careful monitoringofserumlithium concentrationsis recommended during concomitant use.Ifa diurecticis also used, the risk of lithium toxicity may presumably be increased further.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0349 | B.IIl.1.a.4-Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevantPh.Eur.Monograph-Deletion of certificates (incasemultiplecertificatesexistpermaterial)                                                                                                                                                                                                                                                                                                                                                                                      | 27/08/2013 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| WS/0360 | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Update ofSmPC sections 4.2,4.3,4.4 and 4.5 to reflectthat theconcomitantuse ofAngiotensinII Receptor Blockers (ARBs) or Angiotensin-Converting- Enzyme inhibitors (ACEi) with aliskiren is contraindicated inpatients with renal impairment and in patients with diabetes mellitus. Further, section4.4oftheSmPChasbeenupdatedtoinform prescribers that caution is required, and monitoring of blood pressure, renal function and electrolytes is | 27/06/2013 | 31/07/2013 | SmPC, Annex II and PL | Please refer to the Scientific Discussion \"Exforge-Copalia- Dafiro-Imprida-EMEA-H-C-xxxx-WS-360-AR\".                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | recommended, when co-administering agents acting on the renin angiotensin aldosterone system (RAAS) i.e.ACEi, ARBs or aliskiren as a direct renin inhibitor. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update theSmPC,AnnexII and thePackageLeafletinline withthelatestQRDtemplate,toimplementminor editorial changes in the Package Leaflet and to add thecontactdetailsoftheCroatianlocal representative in the Package Leaflet. C.I.4-Variationsrelatedtosignificantmodifications of theSPCdue inparticular to newquality,pre- clinical,clinical orpharmacovigilance data   |            |            |             |                                                                                                                                                                                                                           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0270   | B.I.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 01/02/2013 | n/a        |             |                                                                                                                                                                                                                           |
| IG/0248   | C.I.z-Changes (Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17/12/2012 | n/a        |             |                                                                                                                                                                                                                           |
| IG/0233   | B.Ill.1.a.2-SubmissionofaneworupdatedPh.Eur. CertificateofSuitabilitytotherelevantPh.Eur. Monograph-Updatedcertificatefroman already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13/11/2012 | n/a        |             |                                                                                                                                                                                                                           |
| WS/0249/G | Thiswasanapplicationforagroupofvariations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/09/2012 | 25/10/2012 | SmPC and PL | The safety update of the SmPC and Package Leaflet was based on a review of the MAH's safety and clinical trial data bases,publishedliteratureforboththeamlodipineand valsartan components, a recommendation by the US FDA |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             | frequencydatareported intheliterature areinconsistent. However, as angioedema is a potentially life-threatening andfataladverseeffect,thereviewedliteraturehighlights thatACE-inhibitorsorARBsshouldbeusedwith caution in patients with any history of this condition. ThesafetydataprovidedbytheMAHisregardedas sufficient in order to justify the proposed warning on angioedema'insection4.4of theSmPC.Itshouldalsobe noted that a warning regarding 'angioedema' is already included in the SmPC for Diovan (valsartan monotherapy). Additional changestothewordingofwarningsalready included inSmPCsection 4.4(\"renal arterystenosis\", \"heartfailure”and\"aorticandmitralvalvestenosis\")were alsomadeaspartofthisprocedureinordertoprovide further claritytothehealthcareprofessional. In addition, the MAH took the opportunity to update the amlodipinesectionsoftheSmPCin accordancewith the harmonised product information for Norvasc(amlodipine   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0248/G | This was an application for a group of variations followingaworksharingprocedureaccordingto Article20ofCommissionRegulation(EC)No 1234/2008. WS-0248-Gwasagroupofvariationsconsistingof two Type II variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008 as follows: Variation1:Updateofsection4.5oftheSmPCto add information about thepotential druginteraction between amlodipine and simvastatin, and update of | 19/07/2012 | 23/08/2012 | SmPC and PL | Administration of amlodipinewithgrapefruit or grapefruit juiceisnotrecommendedasbioavailabilitymaybe increased insomepatients,resultinginincreasedblood pressure lowering effects. Concomitantuseof amlodipinewithstrongormoderate CYP3A4inhibitors(protease inhibitors, azole antifungals, macrolideslikeerythromycin orclarithromycin,verapamil or diltiazem)may give rise to significant increase in amlodipineexposure.Theclinical translation of these pharmacokineticvariationsmaybemorepronouncedinthe elderly.Clinical monitoring anddoseadjustmentmay thus be required.                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | theexisting amlodipineinformation insection 4.5in linewiththereviseddruginteractionssectionfor Norvasc(amlodipine monotherapy).ThePackage Leaflet has been updated accordingly; Variation2:Updateofsection4.5oftheSmPCto addinformation aboutthepotential druginteraction betweenvalsartanandinhibitorsoftheuptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir). The Package Leaflet has been updated accordingly. C.I.4-Variationsrelatedtosignificantmodifications of theSPC due inparticular to new quality,pre- clinical,clinical orpharmacovigilance data C.I.4-Variationsrelated tosignificantmodifications of theSPC due inparticular to new quality,pre- clinical, clinical or pharmacovigilance data   |            |     | ThereisnodataavailableregardingtheeffectofCYP3A4 inducerson amlodipine.Theconcomitantuse of CYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give alowerplasmaconcentrationofamlodipine.Amlodipine shouldbeusedwithcautiontogetherwithCYP3A4 inducers. Co-administrationofmultipledosesof10mg amlodipine with80mg simvastatinresultedina77%increase in exposuretosimvastatincomparedtosimvastatin alone.It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine. In animals,lethalventricular fibrillation and cardiovascular collapseareobservedinassociationwithhyperkalaemia afteradministrationofverapamilandintravenous dantrolene.Due toriskofhyperkalaemia,it is recommended thattheco-administrationofcalcium channel blockerssuch as amlodipinebe avoided inpatients susceptible tomalignanthyperthermia and in the management of malignanthyperthermia. In clinical interaction studies, amlodipine did not affect the pharmacokineticsofatorvastatin，digoxin,warfarinor ciclosporin. Theresultsof an invitro study withhumanliver tissue indicatethatvalsartanisasubstrateof thehepaticuptake transporterOATPiB1andof thehepaticeffluxtransporter MRP2.Co-administration ofinhibitors of the uptake transporter(rifampicin,ciclosporin)oreffluxtransporter   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0209/G | Thiswas an applicationfor a groupofvariations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17/08/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | C.I.9.b-Changes to anexisting pharmacovigilance system as described in the DDPS - Change in the contactdetailsoftheQPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                     |            |            |                         |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------|
| WS/0282 | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. toadd anewspecificationparameterforimpuritiesin the active substance. B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent -Addition of a new specification parameter to the specification with its                                                                 | 19/07/2012 | 19/07/2012 | correspondingtestmethod |
|         | This was an applicationfor a group of variations. B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in themanufacturer of ASor of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere | 09/07/2012 | n/a        | IG/0199/G               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | batch control/testing takes place A.5.b-Administrative change -Change in the name and/oraddressofamanufacturerofthefinished product, including quality control sites (excluding manufacturerfor batchrelease) B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate ofSuitability to therelevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0251/G | Thiswasanapplicationforagroupofvariations followingaworksharingprocedureaccording to Article20of CommissionRegulation(EC)No 1234/2008. WS-0251-G is a group of two variations (one type II &onetypeIB)following aworksharingprocedure as follows: -TypeIIvariation:Updateof section4.6of the SmPCwithwording onfertility in linewiththeSmPC for Diovan (valsartan monotherapy) and 5.3 of the SmPCtoimplementthechangestotheSmPCfor Diovan that was approved as part of a recent Article 30(referral)procedure; - Type IB variation: Update of sections 4.6 and 5.3 of theSmPCtoimplementthechangestotheSmPCfor Norvasc (amlodipine monotherapy) that was approved as part of a recent Article 30 (referral) procedure. C.I.1.b - Change in the SPC, Labelling or PL following areferralprocedure-Theproductisnotcovered by | 24/05/2012 | 28/06/2012 | SmPC | The safety of amlodipine in human pregnancy has not been established.Reproductivestudiesinrats andmicehave showndelayeddateofdelivery,prolongeddurationof labour anddecreasedpupsurvival atdosages approximately 50 times greater than the maximum recommendeddosageforhumansbasedonmg/kg.Use in pregnancy is only recommended when there is no safer alternativeandwhenthediseaseitselfcarriesgreaterrisk for the mother andfoetus. Reversiblebiochemicalchangesintheheadofspermatozoa havebeenreportedinsomepatientstreatedbycalcium channelblockers.Clinical data areinsufficientregardingthe potentialeffect of amlodipine onfertility.Therewasno effectonthefertilityofratstreatedwithamlodipine(males for64daysandfemales14dayspriortomating)atdoses up to 10 mg/kg/day (8 times* the maximum recommended humandoseof10mgonamg/m2basis).Inanotherrat studyinwhichmaleratsweretreatedwithamlodipine besilatefor30daysatadosecomparablewiththehuman dose based on mg/kg, decreased plasma follicle-stimulating hormoneandtestosteronewerefound aswellasdecreases inspermdensityandinthenumberofmaturespermatids |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| thedefinedscopeofthereferralbutthechange implementstheoutcomeofthereferralandnonew additional data aresubmitted by theMAH C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                           | tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 timesthemaximumrecommendedhumandoseona mg/m2basis(calculations assume anoral doseof320 mg/day and a 60-kgpatient). Inmarmosetsatsimilardoses,thechangesweresimilar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine. Hypertrophy of the renal juxtaglomerular cells was also seen inboth species.All changes were considered tobe caused by the pharmacological action of valsartan which producesprolongedhypotension,particularlyin marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0148/G | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the majorcontractualarrangementswithotherpersons ororganisationsinvolvedinthefulfilmentof pharmacovigilanceobligations anddescribedinthe DD C.I.9.h -Changes to an existingpharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system | 22/02/2012 | n/a        |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| R/0050    | Renewalofthemarketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                      | 22/09/2011 | 21/11/2011 | SmPC, Annex II, Labelling | BasedontheCHMPreviewof theavailableinformationand on the basis of a re-evaluation of the benefit risk balance,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            | and PL      | theCHMPwasof the opinion that the quality,safety and efficacy of thismedicinal productcontinues tobe adequatelyandsufficientlydemonstratedandtherefore consideredthatthebenefitriskprofileofImpridacontinues tobefavourable. The CHMP recommended the renewal of the Marketing AuthorisationforImprida,subjecttotheconditions aslaid down inAnnexIItotheOpinion.TheCHMPwasalsoof the opinion that the renewal can be granted with unlimited validity. Therenewalrequiredamendmentstothetermsofthe CommunityMarketingAuthorisationbasedon theCHMP's request to implement the latest QRD template. Therefore, theCHMPrecommended thefollowingannexestobe   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0100/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Summary of Product Characteristics and Package Leaflet This was an applicationfor a group ofvariations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. C.I.4-Variations related to significant modifications of theSummaryofProductCharacteristicsduein | 23/06/2011 | 27/07/2011 | SmPC and PL | WS-0100-Gwassubmittedforagroupofvariations consisting of three Type II variations following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Thefollowingvariationwasnotconsideredacceptableby the CHMP: - Variation 1 (scope as applied for by the MAH): Update of section 5.1 of the SmPC with information on efficacy in patientswithstage2hypertensionandblackpatients basedon studiesVAA 2402 andVAA2403. The following variations were considered acceptable by the CHMP: -Variation2:Deletionof thecurrentparagraphinsection 5.1oftheSmPCthatprovidesinformationontherelative                                    |

<div style=\"page-break-after: always\"></div>

|           | particular to new quality, pre-clinical, clinical or pharmacovigilance data C.I.4-Variationsrelated to significantmodifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data C.I.4-Variations related to significant modifications of theSPCdueinparticular tonewquality,pre- clinical, clinical or pharmacovigilance data C.I.4 -Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |     | efficacyofvalsartan/amlodipine80/5mgcomparedto amlodipine 10mg inrelation to theincidence of oedema.In addition, the MAH took the opportunity to update the SmPC in line with the latest QRD template and to update the contact details of the local representatives in the Package Leaflet. -Variation3:Update of section5.1of theSmPCwith information on efficacy in obese patients. [crossreference toScientificdiscussionofadoptedCHMP Assessment Report].   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0088/G | Thiswas anapplicationfor a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons ororganisationsinvolvedinthefulfilmentof pharmacovigilanceobligations anddescribed inthe DD C.I.9.h-Changes to an existingpharmacovigilance system as described in the DDPS - Other change(s) to theDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system                                                         | 11/07/2011 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IG/0074/G | This was an application for a group of variations. B.I.a.2.a-Changes in the manufacturingprocess of theAS-Minorchange in themanufacturingprocess of theAS B.1.b.1.c-Change in the specification parameters                                                                                                                                                                                                                                                                                                                           | 17/06/2011 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent-Additionof anew specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.I.b.2.a-Change in testprocedure forAS or starting material/reagent/intermediate - Minor   |            |            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| IG/0058   | B.Ill.1.a.2-Submissionof aneworupdatedPh.Eur. CertificateofSuitabilitytotherelevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/04/2011 | n/a        |
| WS/0088/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/02/2011 | 17/02/2011 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 1234/2008. to change the specification limit for an impurity in the active substance； toaddnewtestproceduresforthe activesubstance toaddnewspecificationsintheactivesubstance todeletea testprocedurefortheactivesubstance. B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.1.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.b-Change in testprocedure forASor startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,ifan alternativetest procedure is already authorised   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |          |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|
| IG/0032/G | This was an applicationfor a group of variations. ToupdatetheDetailedDescriptionofthe Pharmacovigilance System (DDPS) to version 9.0, to include: -a changeinthedeputyof theQualifiedPersonfor Pharmacovigilance (QPPV); - a change in the major contractual arrangements. - administrative changes not impacting the operation of the pharmacovigilance system. AnnexII.Bhas alsobeenupdated with thelatest wording as per October 2010 CHMP procedural announcement. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-upprocedureoftheQPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisationsinvolved in thefulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) | 21/12/2010 | n/a | Annex II |

<div style=\"page-break-after: always\"></div>

|           | the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| N/0049    | Minor change in labelling or package leaflet not connected with the SPC (Art.61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 20/12/2010 | n/a | PL |
| IG/0028   | B.II.b.1.a-Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/11/2010 | n/a |    |
| IB/0048/G | Thiswasanapplicationforagroupofvariations. B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificateof Suitability to therelevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.1 - Submission of a new or updated Ph. Eur. Certificate ofSuitability to therelevantPh.Eur. Monograph - New certificate from an already approved manufacturer B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionof anew specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting | 24/06/2010 | n/a |    |

<div style=\"page-break-after: always\"></div>

|           | significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof                                                                                                                                                                                                                                                                                                             |            |            |                        | specification limits   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------|
| IA/0047/G | Thiswas an applicationfor a group of variations. B.II.e.5.a.1-Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets,ampoules,etc.)in a pack-Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 01/06/2010 | 01/06/2010 | SmPC, Labelling and PL |                        |
| I1/0046   | Changes to QPPV UpdateofDDPS(Pharmacovigilance)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18/02/2010 | 19/03/2010 | Annex II               |                        |
|           | IA_07_b_01_Replacement/add.ofmanufacturing site:Primarypackaging site-Solidforms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/11/2009 | n/a        |                        | IA/0044                |

<div style=\"page-break-after: always\"></div>

| II/0042   | Change in the manufacturing process of the drug substanceValsartan;addition of analternative processforthe synthesis ofone of the compound used. Quality changes                    | 19/11/2009   | 25/11/2009   |             |                                                                                                                                                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0045   | IA_o7_a_Replacement/add.of manufacturing site: Secondary packaging site                                                                                                             | 25/11/2009   | n/a          |             |                                                                                                                                                                                                                               |
| IB/0043   | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                          | 24/11/2009   | n/a          | SmPC        |                                                                                                                                                                                                                               |
| I1/0038   | To tighthen thespecification,modifytestprocedures andintroducenew onesforthe active substance valsartaninordertoupdate theTestingMonograph of valsartan. Quality changes            | 24/09/2009   | 05/10/2009   |             |                                                                                                                                                                                                                               |
| IA/0041   | IA_11_a_Change inbatch size of active substance or intermediate - up to 10-fold                                                                                                     | 13/08/2009   | n/a          |             |                                                                                                                                                                                                                               |
| IA/0040   | IA_O4_Change in name and/or address of a manuf. of the active substance(no Ph.Eur.cert.avail.)                                                                                      | 28/07/2009   | n/a          |             |                                                                                                                                                                                                                               |
| IA/0039   | IA_o9_Deletionofmanufacturingsite                                                                                                                                                   | 28/07/2009   | n/a          |             |                                                                                                                                                                                                                               |
| II/0035   | TheMAHappliedfor anupdateof theSPCsection 4.6 aswellasPL section 2toimplement the CHMP recommendation on a harmonised labelling relating totheuseofAngiotensinIIReceptorAntagonists | 19/02/2009   | 27/03/2009   | SmPC and PL | AvailabledataregardinguseofAllRAsduringlactation have been assessed. There are no concrete data to support the contraindication of use of AlIRAs during breast-feeding. AllAlIRA agentswerefoundin themilkof lactatingratsbut |

<div style=\"page-break-after: always\"></div>

|         | during pregnancy and lactation. Furthermore, minor typographical changes have been introduced to SPC sections 4.3 and 4.4. Update of Summary of Product Characteristics and Package Leaflet            |            |            |             | no human data about their transfer into breast milk are available.There is only a theoreticalpresumption of low transport according to theirhigh plasmaproteinbinding and low oral availability. A harmonised wording recommendinganaltermativetreatmentwithbetter established safety profiles during breast-feeding, especially while nursing a newborn or preterm infant, has been includedinthesection4.6oftheSPCandsection2of the PL.                                                                                                                                                                                                                                                  |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0037 | IB_14_b_Change in manuf.of active substance withoutPh.Eur.certificate-newmanufacturer                                                                                                                  | 13/03/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0036 | IA_04_Change in name and/or address of a manuf. of the active substance (noPh.Eur.cert.avail.)                                                                                                         | 24/02/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| I1/0031 | Update of SPC section 4.8 and PL section 4 regarding the safety information presented for the individual componentsofthecombinationproduct. UpdateofSummaryofProductCharacteristicsand Package Leaflet | 18/12/2008 | 13/02/2009 | SmPC and PL | Followingtheassessmentofthe2ndPSUR theCHMP) requested the addition of the terms \"myocardial infarction\" and \"arrhythmia\" to SPC section 4.8 with the frequency \"not known\" because several cases were received during the reporting period of the PSuR and these Adverse Drug Reactionsarealsoseeninconnectiontothetreatmentwith amlopdipine. Furthermore,additional informationregarding thepotential decreasesinhaematocritandhaemoglobinlevelsforthe individualcomponentvalsartanwasincludedbasedona review which revealed that the information on laboratory evaluation is not inline withmonotherapySPC. ThePackageLeaflethasbeenupdatedtoensure consistencywith section4.8of theSPC. |
| IB/0032 | IB_14_b_Change inmanuf.of active substance withoutPh.Eur.certificate-newmanufacturer                                                                                                                   | 31/10/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IA/0034   | IA_11_a_Change in batch size of active substance or intermediate-upto10-fold                                                                                                  | 23/10/2008   | n/a        |             |                                                                                                                                                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0033   | IA_11_a_Change inbatch size of active substance or intermediate - up to 10-fold                                                                                               | 23/10/2008   | n/a        |             |                                                                                                                                                |
| IB/0029   | IB_33_Minor change in themanufacture of the finished product                                                                                                                  | 25/07/2008   | n/a        |             |                                                                                                                                                |
| IB/0028   | IA_O8_a_Change in BR/QC testing - repl./add. of batch control/testing site IB_O7_c_Replacement/add.ofmanufacturing site: All other manufacturing operations ex. batch release | 23/07/2008   | n/a        |             |                                                                                                                                                |
| IA/0030   | IA_07_a_Replacement/add.of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add.of manufacturing site: Primary packaging site - Solid forms                | 10/07/2008   | n/a        |             |                                                                                                                                                |
| IA/0027   | IA_32_a_Change inbatchsizeof thefinishedproduct - up to 10-fold                                                                                                               | 07/07/2008   | n/a        |             |                                                                                                                                                |
| IB/0025   | IB_12_b_02_Change in spec.of active subst./agent in manuf.ofactivesubst.-testparameter                                                                                        | 03/07/2008   | n/a        |             |                                                                                                                                                |
| IA/0026   | IA_04_Change in name and/or address of a manuf. of the active substance(no Ph.Eur.cert.avail.)                                                                                | 24/06/2008   | n/a        |             |                                                                                                                                                |
| I1/0019   | TheMAHappliedfor anupdateof theSPCsections 4.3, 4.4, and 4.6 as well as PL section 2 to implementtheCHMPrecommendationona                                                     | 24/04/2008   | 10/06/2008 | SmPC and PL | Cooper'sstudypublished intheNEJM inJune2006 identifiedasignalofincreasedriskofcongenital malformations,particularlycardiacdefectsafterexposure |

<div style=\"page-break-after: always\"></div>

|         | harmonisedlabellingrelatingtotheuseofACE inhibitors and Angiotensin II Receptor Antagonists during pregnancy. Update of Summary of Product Characteristics and Package Leaflet   |            |            |                        | to ACE inhibitors during the first trimester of pregnancy. Since theroleofconfoundingfactorssuchasdiabetesand hypertension cannot be accurately defined based on the availabledata,theteratogenicpotential ofACEinhibitorsis notdemonstrated，eventhoughdatasuggestthatsuch exposure cannotbe considered as safe and should be avoided. Therearefewerdataregardingtherisksassociatedwith first trimester exposure to Angiotensin II receptor antagonists(AIIRAs) than forACE inhibitors.Nevertheless, there is noevidence thattheriskislowerforAIIRAs,and it is considered thatanyconclusionsonACEinhibitors are also valid for AIIRAs. Therefore,the existingcontraindicationfor the9-month pregnancy was revised in order to delete the contraindication during the 1st trimester of pregnancy, but toremainthecontraindicationforthe2nd and3rd trimester of pregnancy. In addition, a harmonised wording   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024 | IA_15_a_Submission of Ph.Eur.certificate for active substance - approved manufacturer                                                                                            | 29/05/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| N/0020  | Minorchangeinlabellingorpackageleafletnot connected with theSPC(Art.61.3Notification)                                                                                            | 23/05/2008 | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0023 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                          | 06/05/2008 | 06/05/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0022 | IA_41_a_01_Change inpack size -change in no.of units within range of appr.pack size                                                                                              | 06/05/2008 | 06/05/2008 | SmPC, Labelling and    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                       |            |            | PL                     |         |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------|
| IA/0021 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                               | 06/05/2008 | 06/05/2008 | SmPC, Labelling and PL |         |
| IB/0017 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                            | 10/12/2007 | n/a        | SmPC, Labelling and PL |         |
|         | IA_o7_a_Replacement/add.of manufacturing site: Secondarypackagingsite IA_07_b_01_Replacement/add.ofmanufacturing site:Primarypackagingsite-Solidforms | 19/09/2007 | n/a        |                        | IA/0016 |
| IA/0015 | IA_41_a_01_Change in pack size - change in no. of units within range of appr.pack size                                                                | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0014 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                               | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0013 | IA_41_a_01_Change in pack size - change in no. of units withinrange of appr.pack size                                                                 | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0012 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                               | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |
| IA/0011 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                               | 13/09/2007 | 13/09/2007 | SmPC, Labelling and PL |         |

<div style=\"page-break-after: always\"></div>

|         | IA_41_a_01_Change in pack size -change in no.of units within range of appr. pack size   | 13/09/2007   | 13/09/2007   | SmPC, Labelling and PL   | IA/0010   |
|---------|-----------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------|
|         | IA_41_a_01_Change in pack size -change in no.of units within range of appr. pack size   | 13/09/2007   | 13/09/2007   | SmPC, Labelling and PL   | IA/0009   |
| IA/0008 | IA_41_a_01_Change in pack size -change in no. of units within range of appr. pack size  | 13/09/2007   | 13/09/2007   | SmPC, Labelling and PL   |           |
| IA/0007 | IA_41_a_01_Change in pack size - change in no. of units within range of appr.pack size  | 13/09/2007   | 13/09/2007   | SmPC, Labelling and PL   |           |
|         | IB_14_b_Changeinmanuf.ofactivesubstance withoutPh.Eur.certificate-newmanufacturer       | 13/07/2007   | n/a          |                          | IB/0006   |
| IA/0004 | IA_15_a_Submission of Ph.Eur.certificate for active substance - approved manufacturer   | 27/04/2007   | n/a          |                          |           |
| IA/0003 | IA_11_a_Change inbatch size of active substance or intermediate - up to 10-fold         | 02/04/2007   | n/a          |                          |           |
| IA/0002 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold        | 02/04/2007   | n/a          |                          |           |
| IA/0001 | IA_11_a_Change inbatch size of active substance or intermediate - up to 10-fold         | 02/04/2007   | n/a          |                          |           |